Cancer patients get chance to continue promising treatment in new safety study
NCT ID NCT06246643
Summary
This study allows cancer patients who are already taking regorafenib in other Bayer studies to continue their treatment if it's working for them. Researchers want to understand how safe and tolerable the continued treatment is for people with solid tumors. The study includes 13 participants who will keep taking their current dose while being monitored for side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID MALIGNANT TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
China Medical University Hospital
Taichung, 404327, Taiwan
-
Hopital Claude Huriez - Lille
Lille, Hauts-de-France, 59037, France
-
Hospital Infantil Universitario Nino Jesus | Oncologia Pediatrica
Madrid, 28009, Spain
-
Hôpital Beaujon - Clichy
Clichy, Île-de-France Region, 92110, France
-
Hôpital Paul Brousse - Villejuif
Villejuif, Île-de-France Region, 94800, France
-
Saitama Cancer Center
Kitaadachi-gun, Saitama, 362-0806, Japan
-
Seoul National University Hospital
Seoul, Seoul Teugbyeolsi, 3080, South Korea
Conditions
Explore the condition pages connected to this study.